Teenagers are expected to complain about aches and pains. A sore knee after football practice, a lingering leg ache after a ...

The SMAB will assist the Company in engaging with the US Food & Drug Administration (FDA) regarding the safety and efficacy of its lead immunotherapy product candidate, OST-HER2, for the treatment of ...

After trypsinization, cells were counted and dilutions of 2 × 10 6 cells in 10 μl phosphate-buffered saline were prepared. Each cell line was injected into one nude mouse at three locations: two ...

A research team at Johns Hopkins Medicine has created and trained a machine learning model to calculate percent necrosis (PN)—or, what percentage of a tumor is "dead" and no longer active—in patients ...

Although advances have been made in both surgical and medical management of patients with osteosarcoma, the overall survival of patients with osteosarcoma has remained constant, with no substantial ...

Osteosarcoma is a malignant neoplasm of the bone and is the most common histological form of primary bone cancer. It is most prevalent in children and young adults, as it is associated with the ...

Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. Before 1970, treatment primarily included surgical resection. However, the introduction of ...

While genetic sequencing has previously helped to uncover different subtypes of other cancers, like breast or skin cancer, for which those patients then receive targeted treatment personalised to ...

The Osteosarcoma market presents opportunities in developing novel therapies, with over 25 companies working on 32+ drugs in the pipeline. There is strong focus on Phase III products like HS-20093, ...

Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally poor responses observed from treatment with immune checkpoint ...